Atlas Trials

Anlotinib in Combination With PD1 With Gemcitabine Plus(+)Cisplatin for Unresectable or Metastatic Biliary Tract Cancer

Clinical trial NCT04300959 · UNKNOWN

Trial details

NCT number
NCT04300959
Sponsor
Zhejiang Cancer Hospital
Status
UNKNOWN
Phase
Phase 2
Study type
INTERVENTIONAL
Biliary Tract Cancer
Start date
2020-01-01
Primary completion
2021-01-01
Enrollment
80

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.